AbbVie's Psoriasis Drug Approved For Japan, But The Main Event Is Yet To Come

|
About: AbbVie Inc. (ABBV), Includes: JNJ, LLY, MNTA, MYL, PFE
by: Terry Chrisomalis
This article is exclusive for subscribers.
Summary

AbbVie obtained Japanese approval of SKYRIZI to treat patients with psoriasis.

Additional regulatory approvals for SKYRIZI are expected to take shape in the coming months for both the U.S. and European territories.

Obtaining approval for SKYRIZI in the U.S. and European territories will be important because they are much larger markets than Japan and because Humira is facing biosimilar competition in 2023.

AbbVie has a major advantage, in that SKYRIZI beat out Humira in one  study and Stelara and placebo for psoriasis in another two studies.

AbbVie (ABBV) was able to obtain its first approval for SKYRIZI (risankizumab) in Japan for treating patients with psoriasis. This is good news, but the market opportunity in Japan is not better than